Core Viewpoint - Kenvue's stock price experienced a pre-market increase of 6% following a significant drop of 7.47% due to warnings from the Trump administration linking its pain reliever Tylenol to autism, despite the company maintaining the safety of the product [1] Group 1: Company Performance - Kenvue's stock has declined over 25% in the past six months due to ongoing allegations regarding Tylenol's association with autism [1] - As of the latest report, Kenvue's stock is priced at $17.99, reflecting a pre-market increase of 6.01% [1] Group 2: Legal and Regulatory Context - The Trump administration's warning may lead to an increase in lawsuits against Kenvue, alleging that prenatal exposure to Tylenol causes autism [1] - Kenvue has faced approximately 500 lawsuits since its spin-off from Johnson & Johnson in 2023, although these lawsuits were dismissed earlier in the year by a federal judge due to insufficient evidence linking Tylenol to autism [1] Group 3: Market and Research Insights - Citigroup analysts believe that the judicial risk posed by the Trump administration's warning to Kenvue is limited, although negative news could impact Tylenol's sales [2] - A comprehensive study analyzing data from nearly 2.5 million children in Sweden over 25 years concluded that there is no association between Tylenol use during pregnancy and autism [2] - The UK Health Minister publicly criticized Trump's advice, stating that following such guidance could harm unborn babies, reinforcing that there is no evidence linking acetaminophen use during pregnancy to autism [2]

Group 1: Kenvue and Acetaminophen Controversy - Kenvue's stock rebounded by 6% in premarket trading after a 7.5% drop due to concerns raised by the Trump administration regarding acetaminophen use during pregnancy [3][4]. - The company, a spinoff of Johnson & Johnson, defends acetaminophen as the safest pain reliever for pregnant women, citing rigorous research and endorsements from medical professionals [5]. - The FDA has issued a strong recommendation against the use of acetaminophen during pregnancy, which may lead to potential lawsuits for Kenvue [6]. Group 2: Boeing's Major Order - Boeing received an order from Uzbekistan Airways for up to 22 787 Dreamliner jets, marking the airline's largest-ever purchase [7]. - The order includes 14 787-9 airplanes with options for eight additional jets, aimed at modernizing Uzbekistan Airways' fleet and expanding international routes [8]. Group 3: Meta's New Dating Features - Meta Platforms introduced new features in its Facebook Dating service to combat "swipe fatigue," including a dating assistant chatbot and a "Meet Cute" feature for surprise matches [10][11]. - The introduction of these features negatively impacted shares of rival dating services, with Match Group and Bumble seeing declines of 5.4% and 3% respectively [12].

Kenvue stock rallied on Tuesday off a record low, after a White House press conference didn't offer fresh evidence that could be used by plaintiffs to sue the maker of Tylenol for its alleged link to ... ...

Group 1 - Kenvue's stock experienced a decline of approximately 7.5% yesterday, followed by a pre-market rebound of over 6%, reaching $18.02 [1] - President Trump warned pregnant women against using Tylenol, citing a potential link between acetaminophen and autism, despite the lack of widely accepted scientific evidence [1] - Kenvue issued a statement asserting confidence in independent and reliable scientific evidence that acetaminophen does not cause autism, strongly opposing contrary claims [1]

Core Insights - Kenvue, the maker of Tylenol, experienced a rise in stock prices during European trading despite controversial comments made by U.S. President Donald Trump linking its pain medication to autism risk during pregnancy [1] Company Summary - Kenvue's stock performance indicates resilience in the face of negative publicity, suggesting potential investor confidence in the company's long-term prospects [1] Industry Summary - The incident highlights ongoing concerns regarding the safety of over-the-counter medications during pregnancy, which may impact consumer perception and regulatory scrutiny in the pharmaceutical industry [1]

Core Viewpoint - The potential litigation risks surrounding Kenvue Inc. due to President Trump's comments on Tylenol's link to autism have led to a significant decline in the company's stock price, raising investor concerns about the future of the company [1][2][3]. Company Overview - Kenvue Inc., which was spun off from Johnson & Johnson in 2023, is facing scrutiny over its flagship product, Tylenol, amid allegations that its use during pregnancy may increase autism risk [5]. - The company has a diversified portfolio, including brands like Listerine, Band-Aid, and Bengay, but Tylenol remains a critical product for its revenue [5]. Market Reaction - Kenvue's stock fell by 7.47% to $16.97 per share on Tuesday, with a year-to-date decline of 20.25% and a 26.28% drop over the year [6]. - The stock's performance is characterized by a weaker price trend across short, medium, and long-term evaluations, indicating potential challenges ahead [6]. Legal and Scientific Response - In light of the controversy, Kenvue has issued a statement on its website asserting that credible scientific data does not support a link between acetaminophen and autism, indicating the company's readiness to address both scientific claims and potential lawsuits [4][5].

Market Overview - U.S. stocks closed higher on Monday, with the Dow Jones Industrial Average up 0.14% to 46,381.54, the S&P 500 increasing by 0.4% to 6,693.75, and the Nasdaq rising 0.7% to 22,788.98 [1] Nvidia Corp. (NVDA) - Nvidia shares rose 3.97% to close at $183.61, reaching an intraday high of $184.55 and a low of $174.71, with a 52-week range of $86.63 to $184.55 [1] - The company announced a significant $100 billion investment to enhance OpenAI's next-gen AI infrastructure, deploying Nvidia-powered systems to support this initiative [1] Kenvue Inc. (KVUE) - Kenvue's stock dropped 7.47% to close at $16.97, with a high of $17.96 and a low of $16.89, and a 52-week range of $16.89 to $25.17 [2] - The stock spiked 4.4% in after-hours trading to $17.72, following news of a potential announcement from the Trump administration regarding health concerns over acetaminophen in Tylenol, which could impact Kenvue's product sales [2] Rivian Automotive Inc. (RIVN) - Rivian's stock surged 5.98% to $15.24, with an intraday high of $15.43 and a low of $14.11, and a 52-week range of $9.50 to $17.14 [3] - The company held a kickoff ceremony for its new Georgia plant, expected to create thousands of jobs and support its global expansion [3] MicroCloud Hologram Inc. (HOLO) - MicroCloud Hologram saw a 6.72% increase, closing at $5.56, with a high of $5.68 and a low of $4.90, and a 52-week range of $4.16 to $375.20 [4] - In after-hours trading, the stock shot up over 22% to $6.80, following the proposal of an innovative solution for controlling quantum photonic states, which could have significant applications in quantum optics [4] Opendoor Technologies Inc. (OPEN) - Opendoor's shares fell 12.43% to $8.38, with a high of $9.45 and a low of $8.32, and a 52-week range of $0.51 to $10.87 [5] - In after-hours trading, the stock fell by 5.7% to $7.90, following a rally sparked by hedge fund manager Eric Jackson's announcement of a position in Better Home & Finance, leading to a shift in investor focus [5] Stock Rankings - Benzinga's Edge Stock Rankings indicate Nvidia stock has a Value in the 4th percentile but Momentum in the 86th percentile [6]

Group 1 - The Trump administration has issued warnings regarding the risks associated with the use of a specific product during pregnancy, which the company disputes [1]

Kenvue shares fell over 7% to a record low during Monday's session ahead of an announcement at the White House. The stock climbed in after-hours trading. Tylenol maker Kenvue said that scientific studies showed that there was no link between acetaminophen and autism. Justin Sullivan / Getty Images Close KEY TAKEAWAYS Shares of Tylenol maker Kenvue (KVUE) dropped Monday ahead of an anticipated report by the Trump administration linking pregnant women's use of the painkiller to autism. Investopedia requires w ...

For more, let's bring in Dr.. Ashish Jaw, uh, dean of Brown University School of Public Health and former White House COVID response coordinator during the Biden administration. Dr.. Jaw, great to have you with us. This physician's notice uh, on acetaminophen for use during pregnancy. It doesn't seem as stringent as perhaps the markets had expected because it says that basically it allows doctors or doesn't allow, but it says you can still take it um, but you should limit it. Um, is that not as as bad as yo ...